Adaptive Biotechnologies
ADPT
283 hedge funds and large institutions have $2.44B invested in Adaptive Biotechnologies in 2025 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 101 increasing their positions, 91 reducing their positions, and 38 closing their positions.
79% more call options, than puts
Call options by funds: $1.48M | Put options by funds: $825K
37% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 38
12% more capital invested
Capital invested by funds: $2.18B → $2.44B (+$266M)
11% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 91
4% more funds holding
Funds holding: 271 → 283 (+12)
2.94% more ownership
Funds ownership: 95.5% → 98.44% (+2.9%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$66.3M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$53.9M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$36.2M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$30.3M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$27.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$55.2M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$31.5M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
-$27.8M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$27.8M |
| 5 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
-$27.2M |
ADPT Hedge Fund Activity: Q4 2025 in Review
283 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q4 2025, worth a combined $2.44B — up 12% from $2.18B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new ADPT positions and 38 closed out — a net gain of 14 holders — while 101 added to existing stakes and 91 trimmed.
The largest buyer was Westfield Capital Management, opening a new position worth an estimated $66.3M. The largest seller was Ameriprise, cutting an estimated $55.2M.
- 283 institutional investors held Adaptive Biotechnologies (ADPT) as of Q4 2025, up from 271 in Q3 2025.
- Funds reported $2.44B of Adaptive Biotechnologies stock for Q4 2025, up 12% quarter-over-quarter.
- 52 funds opened new Adaptive Biotechnologies positions in Q4 2025 and 38 closed out, a net change of +14 holders.
- The largest Adaptive Biotechnologies buyer in Q4 2025 was Westfield Capital Management, an estimated $66.3M added.
- The largest Adaptive Biotechnologies seller in Q4 2025 was Ameriprise, an estimated $55.2M sold.
Based on aggregated 13F filings for Q4 2025.